X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Cetrorelix Acetate is used to prevent premature ovulation during controlled ovarian stimulation. Cetrorelix blocks the effects of a natural hormone, called GnRH. GnRH controls the secretion of another hormone, called LH, which induces ovulation during the menstrual cycle.
Lead Product(s): Cetrorelix Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 27, 2022
Details:
Cetrorelix Acetate for Injection 0.25 mg is used to prevent premature ovulation during controlled ovarian stimulation, for Injection blocks such undesirable premature ovulation.
Lead Product(s): Cetrorelix Acetate
Therapeutic Area: Obstetrics/Gynecology (Women’s Health) Product Name: Cetrorelix Acetate-Generic
Highest Development Status: ApprovedProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 16, 2022
Details:
Under the deal, Théa Pharma acquired seven products including established glaucoma therapies Zioptan®, Cosopt®, Cosopt® PF, and Betimol®, along with Azasite®, Akten®, and the ocular surface repair agent AcellFX™.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Zioptan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Théa Pharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition March 09, 2022
Details:
The purchase will add seven established brands, including Akorn’s leading glaucoma therapy, Zioptan®, to Théa’s portfolio. Théa will also welcome Akorn’s nearly 50-person sales force, which Théa expects to expand in support of anticipated growth and launches of additional products in the U.S.
Lead Product(s): Tafluprost
Therapeutic Area: Ophthalmology Product Name: Zioptan
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Laboratoires Thea
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 28, 2022
Details:
The Consumer Health business primarily consists of the following over-the-counter brands: TheraTears , Diabetic Tussin , MagOx , Multi-betic , and Zostrix.
Lead Product(s): Sodium Carboxymethylcellulose
Therapeutic Area: Ophthalmology Product Name: TheraTears
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Prestige Consumer Healthcare
Deal Size: $230.0 million Upfront Cash: $230.0 million
Deal Type: Divestment May 27, 2021
Details:
Loteprednol Etabonate Ophthalmic Gel, 0.5% is indicated for the treatment of post-operative inflammation and pain following ocular surgery.
Lead Product(s): Loteprednol Etabonate
Therapeutic Area: Ophthalmology Product Name: Undisclosed
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 11, 2021
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
